ArticleBrain sciences2022
MOGAD Involving Cranial Neuropathies: A Case Report and Review of Literature.
Article in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- MOGAD update: new phenotypes in the expanding clinical spectrum.Journal of neurology · 2026Review
- Clinical, imaging, and immunotherapeutic features in MOGAD: a retrospective real-world cohort in Northern China.Therapeutic advances in neurological disorders · 2026Article
- Isolated Sixth Cranial Nerve Palsy as the First Presenting Sign of MOG Antibody-Associated Disease in a Three-Year-Old Child.The British and Irish orthoptic journal · 2026Article
- The relationship between serum MOG-IgG titer status and titers and the prognosis of pediatric MOGAD: a retrospective cohort study.Frontiers in pediatrics · 2026Article
- Late-onset myelin oligodendrocyte glycoprotein antibody-associated disease: an underrecognized entity in clinical practice; what does its course in later life teach us? A case report and narrative review.Postepy psychiatrii neurologii · 2025Article
- MOGAD: A Shifting Landscape-From Pathogenesis to Personalised Management, Global Perspectives and Latin American Insights.Biomedicines · 2025Review
- Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as aseptic meningitis and multiple cranial neuritis: a case report.BMC neurology · 2025Article
- Pediatric Anti-MOG Antibody-Associated Disease (MOGAD) with Coexisting Myasthenia Gravis: A Rare Association.Annals of Indian Academy of Neurology · 2025Article
- A case of MOGAD with rectal adenocarcinoma: Comorbidity or paraneoplastic neurological syndrome?Brain, behavior, & immunity - health · 2025Article
- MOG positive primary autoimmune meningitis mimicking tuberculous meningitis: a case series.BMJ neurology open · 2025Article
- Cranial Nerve Involvement Apart from Optic Nerve in MOG-Antibody Disease: Putative Mechanisms.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Myelin-oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an autoimmune-mediated demyelinating disease of the central nervous system (CNS). Patients with MOGAD may develop any combination of optic neuritis (ON), myelitis, brainstem syndrome and encephalitis. Reports of MOGAD with cranial nerve involvement are rare. Herein, we report a MOGAD patient with cranial neuropathies. In addition, we summarized the clinical features of the previously reported six MOG-IgG-positive cases with cranial nerve involvement and discussed the underlying mechanisms of MOGAD involving cranial nerves. Cranial neuropathy is an emerging phenotype in MOGAD, which has characteristics of both central and peripheral nervous system (PNS) involvement, with the trigeminal nerve being the most commonly affected nerve. MOG antibody testing in patients with cranial neuropathies is warranted, and immunotherapy is advocated when the risk of relapse is high. Although higher antibody titers and persistently positive serological test results are predictive of disease recurrence, the long-term outcomes of MOG-IgG-positive patients with cranial neuropathies remain largely unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.